WTWeijing Tao

Weijing Tao

*This is an algorithmically generated author record based on publicly available information.

Weijing Tao has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aggressive Metastasis With Silent PET/CT

    by Miaomiao Mm Xie, Hongchao Mm Zhu, Haiyan Mm Liu, Rui Mm Sun, Weijing Tao

    Primary splenic angiosarcoma is a rare, aggressive malignancy carrying a poor prognosis. A 65-year-old woman with a pathologically confirmed well-differentiated splenic angiosarcoma developed liver metastases 5 months into follow-up. Subsequent 18 F-FDG and 68 Ga-FAPI PET/CT imaging revealed a “dual-negative” pattern, demonstrating no significant radiotracer uptake in the metastatic liver lesions. Despite well-differentiated histology, the tumor showed rapid progression, confirming aggressive behavior in well-differentiated angiosarcoma. The high-grade splenic angiosarcoma demonstrated negative findings on dual-tracer PET/CT, underscoring that vigilance and comprehensive multimodal evaluation are crucial for such occult malignancies.


  • Open Access

    PSMA-RADS 2.0: clinical validation and technical considerations for prostate-specific membrane antigen positron emission tomography/computed tomography image interpretation

    by Luyi Cheng, Chaobo Jin, Huai Zhang, Zhuxu Sun, Junfu Fan, Tianshuo Yang, Fei Mao, Guangbo Fu, Qiuhu Wang, Xiaobing Niu, et al.

    Background: The updated diagnostic framework prostate-specific membrane antigen Reporting and Data System 2.0 (PSMA-RADS 2.0) has been introduced as a standardized scoring system for PSMA positron emission tomography/computed tomography (PET/CT) structured reporting to enhance the accuracy and clinical utility of prostate cancer (PCa) lesion interpretation. This study aims to evaluate the reliability and identify potential limitations of PSMA-RADS 2.0 in clinical applications. Methods: We conducted a comparative analysis between PSMA-RADS versions 1.0 and 2.0, followed by prospective evaluation of 109 lesions using PSMA-RADS 2.0 criteria. Inter- and intra-reader consistencies were analyzed statistically to evaluate the reliability and practicality of the scoring system. In the context of two independent readings, the inter-reader consistency between experienced readers (ERs) and inexperienced readers (IRs) was evaluated using the intra-class correlation coefficient (ICC). Results: Compared to version 1.0, PSMA-RADS 2.0 simplified primary PSMA-RADS-1 classification for Category I lesions and introduced PSMA-RADS-5T for post-treatment assessment. Inter-reader correlation coefficients values demonstrated excellent consistency (ERs: 0.964–0.969; IRs: 0.929–0.932). Intra-reader correlation coefficients ranged from 0.920 to 0.985 across all readers. However, challenges persisted in lymph node interpretation (ICC: 0.797–0.823) and post-treatment classification. Conclusions: PSMA-RADS 2.0 provides a reliable framework for PSMA PET/CT interpretation, even for IRs. Further refinement is needed for post-treatment categorization and lymph node differentiation. The proposed PSMA-RADS-5T sub-classification complete remission/partial remission/stability disease/progression disease (CR/PR/SD/PD) may enhance clinical utility for treatment monitoring.


  • Open Access

    Extensive bone metastases from an occult gastric primary: A case report

    by Chao-Bo Jin, Yong-Sheng Li, Juan Zhang, Jian Wu, Wei-Jing Tao

    BACKGROUND This report describes a rare case of a small gastric cancer lesion with widespread bone metastases and markedly elevated alkaline phosphatase levels that was initially misdiagnosed as rheumatoid arthritis, as the patient’s sole clinical manifestation was chronic bone pain persisting for 1 year. CASE SUMMARY An 83-year-old man was admitted due to worsening generalized joint pain over 1 year. Serum alkaline phosphatase levels were markedly elevated, and technetium-99m methylene diphosphonate single-photon emission computed tomography (CT) and fluorine-18 sodium fluoride positron emission tomography (PET)/CT images showed symmetrical diffuse uptake of the radiotracers throughout the skeleton. Initially, Paget’s disease was suspected, but abnormal hematologic tumor markers and bone biopsy confirmed metastatic adenocarcinoma. Fluorine-18-fluorodeoxyglucose PET/CT did not reveal a primary tumor. The patient had a history of colon polypectomy and tubulovillous adenoma with atypical hyperplasia on pathological examination 10 years prior. Further investigation using gallium-68-labeled fibroblast-activation protein inhibitor PET/CT images showed increased punctate uptake in the gastric antrum. Gastroscopy demonstrated a 1.0 cm ulcerated mass in the prepyloric region, and histopathological evaluation of the biopsy specimen revealed poorly differentiated adenocarcinoma. The incidence of bone metastases from gastric cancer is very low, especially with such extensive involvement. CONCLUSION Occult gastric carcinomas with bone metastases necessitate proactive high-risk surveillance and multidisciplinary integration to improve diagnostic accuracy and clinical outcomes.


  • Open Access

    The Characteristics of Prostate Mucinous Adenocarcinoma Visualized by 68Ga-PSMA, 68Ga-FAPI, and 18F-FDG PET/CT

    by Zhuxu Mm Sun, Xi Jiang, Guangbo Fu, Suan Mm Sun, Weijing Tao

    Primary prostate mucinous adenocarcinoma is an exceedingly rare entity with distinct imaging characteristics. We report the case of a 62-year-old man with biopsy-proven prostate mucinous adenocarcinoma. The patient underwent MRI and multi-tracer PET/CT. PET/CT images demonstrated the prostate lesion with moderate uptake of 68Ga-PSMA and 68Ga-FAPI, yet significantly high 18F-FDG uptake. No abnormal radiotracers’ uptake was observed elsewhere in the body. Multi-tracer PET/CT findings suggest that 18F-FDG may be a more suitable radiotracer for the systemic assessment of primary prostate mucinous adenocarcinoma.


  • Development and clinical evaluation of [68Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring

    by Weijing Tao, Jinglin Zhang, Xin Meng, Xuedong Han, Qiuhu Wang, Yixiang Lin, Luyi Cheng, Minmin Liu, Dongzhu Da, Huai Zhang, et al.

    Purpose Accurate assessment of human epidermal growth factor receptor type 2 (HER2) expression is crucial for diagnosis, treatment planning, and monitoring of breast cancer patients. A 68Ga-labeled tracer based on the albumin-binding domain-derived affinity protein 6 (ADAPT6) was developed to evaluate HER2 expression in breast cancer. Methods The gene encoding ADAPT6 was modified with N-terminal (GHEHEHEDANS) and C-terminal (GSSC) extensions to enhance its functionality. The precursor was synthesized, purified, and characterized, followed by radiolabeling with 68Ga to produce [68Ga]Ga-NODAGA-ADAPT6. In vivo metabolism and biodistribution studies were performed in HCC1954 (HER2-positive) and MDA-MB-468 (HER2-negative) tumor-bearing mice. Additionally, with ethical approval and informed consent, 22 breast cancer patients underwent [68Ga]Ga-NODAGA-ADAPT6 PET imaging to assess HER2 expression in primary and metastatic lesions. Results The tracer was prepared with a radiochemical purity exceeding 99% and demonstrated high stability in vivo. Micro-PET/CT imaging revealed significant accumulation of the radiotracer in HCC1954 tumors, which was markedly reduced after HER2 blockade with trastuzumab. In contrast, MDA-MB-468 tumors showed minimal uptake. In the clinical study, [68Ga]Ga-NODAGA-ADAPT6 PET images displayed varying levels of radiotracer uptake in primary and metastatic lesions, which correlated well with the HER2 expression status determined by pathological analysis. Conclusion [68Ga]Ga-NODAGA-ADAPT6 exhibited excellent pharmacokinetic properties and high specificity for HER2-expressing lesions in PET imaging. These findings highlight its potential as a promising tool for distinguishing different levels of HER2 expression in breast cancer, aiding in personalized treatment strategies.


  • Open Access

    Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma

    by Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao

    Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous hematological malignancy resulting in a range of outcomes, and the early prediction of these outcomes has important implications for patient management. Clinical scoring systems provide the most commonly used prognostic evaluation criteria, and the value of genetic testing has also been confirmed by in-depth research on molecular typing. [18F]-fluorodeoxyglucose positron emission tomography / computed tomography ([18F]FDG PET/CT) is an invaluable tool for predicting DLBCL progression. Conventional baseline image-based parameters and machine learning models have been used in prognostic FDG PET/CT studies of DLBCL; however, numerous studies have shown that combinations of baseline clinical scoring systems, molecular subtypes, and parameters and models based on baseline FDG PET/CT image may provide better predictions of patient outcomes and aid clinical decision-making in patients with DLBCL.


  • Development and validation of prognostic models based on 18F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients

    by Tianshuo Yang, Zhuxu Sun, Yuye Shi, Yue Teng, Luyi Cheng, Ronghua Zhu, Huai Zhang, Qiuhu Wang, Jing Wei, Chongyang Ding, et al.

    This study aimed to assess the predictive value of baseline 18F-FDG PET radiomics features, metabolic parameters, and clinical factors for PFS and OS in elderly DLBCL patients. Using LASSO COX regression, we derived Radscore from PET radiomics features. We constructed and externally validated prognostic models, evaluating their performance through various metrics. From 341 training set patients and 83 external validation set patients revealed significant correlations between PET radiomics features and survival outcomes. Multivariate COX analysis identified associations of radiomics features (Radscore), metabolic parameters (TMTV, Dmax), and clinical factors (ECOG PS, hemoglobin level) with PFS and OS. In external validation, the combined model incorporating radiomic features, metabolic parameters, and clinical factors showed superior predictive performance for PFS and OS compared to other models. The combined model had higher C-index values for both PFS and OS, and its td-ROC curves exhibited significantly higher AUCs. Calibration curves demonstrated good consistency, and DCA revealed a higher net benefit for the combined model. In conclusion, the combined model that incorporated 18F-FDG PET radiomics features, metabolic parameters, and clinical factors demonstrated superior prognostic predictive ability, providing a useful tool for personalized treatment decisions in elderly DLBCL patients.


  • Development and biological evaluation of PSMA/FAP dual targeting radiotracers for prostate cancer imaging

    by Haodong Hou, Jingyue Gao, Yuze Ma, Yuan Pan, Guihua Hou, Weijing Tao, Feng Gao

    Prostate cancer (PCa) is a common malignant cancer in men with a five-year survival rate of 32%. In recent years, positron emission tomography (PET) has been widely used in clinical PCa diagnosis. In this study, we developed two novel PSMA-FAP radiotracers ([68Ga]Ga-PSMA-FAPI-01 and [68Ga]Ga-PSMA-FAPI-02) for PET/CT, aiming to develop PSMA-FAP dual-targeting radiotracers with high selectivity and favourable pharmacokinetic properties for the diagnosis of PCa. We introduced lipophilic groups, based on the glutamic acid–urea–lysine pharmacophore and linked a DOTAGA group for 68Ga labeling. [68Ga]Ga-PSMA-FAPI-01 and [68Ga]Ga-PSMA-FAPI-02 were investigated, compared with [68Ga]Ga-PSMA-11 and [68Ga]Ga-PSMA I&T. Two novel radiotracers were prepared with a radiochemical purity >95%, and excellent stability in vivo and in vitro. Novel radiotracers revealed high receptor affinity towards PSMA and FAP (Ki < 10 nM). The results of micro-PET/CT imaging and biodistribution studies demonstrated that novel radiotracers displayed excellent dual-targeting capability and favorable pharmacokinetic properties, which were also observed in human PET/CT studies. All these indicate that a dual-targeting strategy is available in designing radiotracers for tumor imaging.


  • Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties

    by Haodong Hou, Yuan Pan, Yanzhi Wang, Yuze Ma, Xiaobing Niu, Suan Sun, Guihua Hou, Weijing Tao, Feng Gao

    Purpose A series of new 68Ga-labeled tracers based on [68Ga]Ga-PSMA-617 were developed to augment the tumor-to-kidney ratio and reduce the activity accumulation in bladder, ultimately minimize radiation toxicity to the urinary system. Methods We introduced quinoline group, phenylalanine and decanoic acid into different tracers to enhance their lipophilicity, strategically limiting their metabolic pathway through the urinary system. Their binding affinity onto LNCaP cells was determined through in vitro saturation assays and competition binding assays. In vivo metabolic study, PET imaging and biodistribution experiment were performed in LNCaP tumor-bearing B-NSG male mice. The most promising tracer was selected for first-in-human study. Results Four radiotracers were synthesized with radiochemical purity (RCP) > 95% and molar activity in a range of 20.0-25.5 GBq/μmol. The binding affinities (Ki) of TWS01, TWS02 to PSMA were in the low nanomolar range (< 10 nM), while TWS03 and TWS04 exhibited binding affinities with Ki > 20 nM (59.42 nM for TWS03 and 37.14 nM for TWS04). All radiotracers exhibited high stability in vivo except [68Ga]Ga-TWS03. Micro PET/CT imaging and biodistribution analysis revealed that [68Ga]Ga-TWS02 enabled clear tumor visualization in PET images at 1.5 h post-injection, with higher tumor-to-kidney ratio (T/K, 0.93) and tumor-to-muscle ratio (T/M, 107.62) compared with [68Ga]Ga-PSMA-617 (T/K: 0.39, T/M: 15.01) and [68Ga]Ga-PSMA-11 (T/K: 0.15, T/M: 24.00). In first-in-human study, [68Ga]Ga-TWS02 effectively detected PCa-associated lesions including primary and metastatic lesions, with lower accumulation in urinary system, suggesting that [68Ga]Ga-TWS02 might be applied in the detection of bladder invasion, with minimized radiation toxicity to the urinary system. Conclusion Introduction of quinoline group, phenylalanine and decanoic acid into different tracers can modulate the binding affinity and pharmacokinetics of PSMA in vivo. [68Ga]Ga-TWS02 showed high binding affinity to PSMA, excellent pharmacokinetic properties and clear imaging of PCa-associated lesions, making it a promising radiotracer for the clinical diagnosis of PCa. Moreover, TWS02 with a chelator DOTA could also label 177Lu and 225Ac, which could be used for PCa treatment without significant side effects. Trial registration The clinical evaluation of this study was registered On October 30, 2021 at https://www.chictr.org.cn/ (No: ChiCTR2100052545).


  • Open Access

    Solitary Fibrous Tumor of the Prostate Shown on FAPI PET/CT

    by Tianshuo Mm Yang, Ronghua Mm Zhu, Zhongying Guo, Xiaobing Niu, Weijing Tao

    Solitary fibrous tumors are fibroblast tumors that occur mainly in the peritoneum, extremities, and pleura. Here, we report the MRI, FDG PET/CT, and FAPI PET/CT findings of a rare prostate solitary fibrous tumor. A 57-year-old man was pathologically diagnosed with a solitary fibrous tumor. To detect any systemic metastases or other primary lesions, the patient underwent FDG PET/CT and FAPI PET/CT examination sequentially. Mild FDG uptake was observed in the primary prostatic lesion, but there was a significant uptake of FAPI in the prostate. This case highlighted that FAPI PET/CT may outperform FDG PET/CT in identifying solitary fibrous tumors.